Sciabola Simone, Stanton Robert V, Wittkopp Sarah, Wildman Scott, Moshinsky Deborah, Potluri Shobha, Xi Hualin
Laboratorio di Chemiometria, Universitá di Perugia, Via Elce di Sotto, 10, 1-06123, Perugia, Italy.
J Chem Inf Model. 2008 Sep;48(9):1851-67. doi: 10.1021/ci800138n. Epub 2008 Aug 22.
Kinases are involved in a variety of diseases such as cancer, diabetes, and arthritis. In recent years, many kinase small molecule inhibitors have been developed as potential disease treatments. Despite the recent advances, selectivity remains one of the most challenging aspects in kinase inhibitor design. To interrogate kinase selectivity, a panel of 45 kinase assays has been developed in-house at Pfizer. Here we present an application of in silico quantitative structure activity relationship (QSAR) models to extract rules from this experimental screening data and make reliable selectivity profile predictions for all compounds enumerated from virtual libraries. We also propose the construction of R-group selectivity profiles by deriving their activity contribution against each kinase using QSAR models. Such selectivity profiles can be used to provide better understanding of subtle structure selectivity relationships during kinase inhibitor design.
激酶与多种疾病相关,如癌症、糖尿病和关节炎。近年来,许多激酶小分子抑制剂已被开发出来作为潜在的疾病治疗药物。尽管取得了这些进展,但选择性仍然是激酶抑制剂设计中最具挑战性的方面之一。为了研究激酶选择性,辉瑞公司内部开发了一组45种激酶检测方法。在此,我们展示了一种基于计算机的定量构效关系(QSAR)模型的应用,以从该实验筛选数据中提取规则,并对虚拟库中列举的所有化合物进行可靠的选择性概况预测。我们还建议通过使用QSAR模型推导R基团对每种激酶的活性贡献来构建R基团选择性概况。这种选择性概况可用于在激酶抑制剂设计过程中更好地理解细微的结构选择性关系。